Last edition
News about "AskBio"
Genethon Partners with AskBio on Pompe Gene Therapy
The licensing deal enables AskBio to advance the clinical development of Genethon’s investigational gene therapy for Pompe disease through an industry partnership.
AskBio | 15/01/2026 | By News Bureau
AskBio Reports Safety Data from AB-1003 LGMD 2I/R9 Study
Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with Limb-Girdle Muscular Dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or serious adverse events reported up to 52 weeks post-treatment.
AskBio | 13/10/2025 | By Dineshwori | 127
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy